<i>CYP3A4*22</i> Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

Abstract

Paclitaxel exposure showed a relationship with the severity of paclitaxel-induced neurotoxicity. In this study, female CYP3A4*22 carriers had increased risk of developing severe neurotoxicity during paclitaxel therapy. These observations may guide future individualization of paclitaxel treatment.